Denali Therapeutics (NASDAQ:DNLI) Stock Rating Reaffirmed by HC Wainwright

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $95.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 392.23% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Stifel Nicolaus decreased their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Denali Therapeutics in a research note on Wednesday, February 28th. Finally, UBS Group cut their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.33.

Denali Therapeutics Stock Performance

NASDAQ DNLI traded up $2.45 during trading on Wednesday, hitting $19.30. 492,491 shares of the company’s stock traded hands, compared to its average volume of 1,153,974. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -17.87 and a beta of 1.39. The business has a 50 day moving average of $18.82 and a 200-day moving average of $18.84. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter last year, the firm posted ($0.80) earnings per share. On average, analysts expect that Denali Therapeutics will post -2.61 EPS for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 92,500 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares of the company’s stock, valued at $970,490.50. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ryan J. Watts sold 9,589 shares of Denali Therapeutics stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $165,793.81. Following the transaction, the chief executive officer now owns 238,067 shares of the company’s stock, valued at approximately $4,116,178.43. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock valued at $2,218,802 in the last quarter. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently bought and sold shares of the business. CWM LLC boosted its position in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the period. Assetmark Inc. lifted its position in Denali Therapeutics by 49.1% in the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after acquiring an additional 707 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in shares of Denali Therapeutics in the 4th quarter valued at about $59,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Denali Therapeutics by 96.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock worth $73,000 after buying an additional 1,732 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.